RC48 Monotherapy or Combination With Envafolimab for CDK12 Alterations mCRPC With Standard Treatment Failure

The aim of this study is to evaluate the efficacy and safety of vediximab monotherapy or in combination with enrolizumab for second-line treatment of CDK12 alterations mCRPC that has failed standard therapy. The research results are expected to provide new insights and breakthroughs for the treatment of advanced prostate cancer.

Trial Details

NCT ID

NCT06663007

Phase

PHASE1 / PHASE2

Sponsor

Tianjin Medical University Second Hospital

Status

RECRUITING

Cancer Type

Prostate Cancer

Interventions

RC48
Envafolimab

Locations (sample)

Tianjin, Tianjin Municipality, China|39.14222,117.17667

Key Eligibility Criteria

Participants must be able to understand the procedures and methods of this study, willing to strictly follow the clinical trial protocol to complet…
Patients aged ≥ 18 years old;
Pathological examination confirms non resectable or metastatic HER2 positive castration resistant prostate cancer (mCRPC): HER2 positive is defined…
Carrying CDK12 mutation combined with ERBB amplification (NGS or FISH) or HER2 IHC (1+, 2+, 3+);

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Prostate Cancer Trials on Trialify →